Detalhe da pesquisa
1.
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.
Cell
; 140(5): 652-65, 2010 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20211135
2.
The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
FASEB J
; 33(6): 7647-7666, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30917007
3.
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Blood
; 122(11): 1923-34, 2013 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23926298
4.
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Blood
; 122(17): 3034-44, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23970380
5.
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
J Clin Invest
; 117(9): 2408-21, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17717597
6.
Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.
Sci Signal
; 8(381): ra58, 2015 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26082434
7.
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
J Hematol Oncol
; 6: 21, 2013 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23497456
8.
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
J Clin Invest
; 123(10): 4144-57, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23999433
9.
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
Blood
; 111(2): 816-28, 2008 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17925491